Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 29Carcinoma, Basal Cell 12Melanoma 10Keratosis 4Neoplasm Metastasis 2Skin Neoplasms 1Precancerous Conditions 1Lymphoma, T-Cell, Cutaneous 1Leukoplakia 1Leukokeratosis, Hereditary Mucosal 1Hutchinson's Melanotic Freckle 1Facies 1Carcinoma, Squamous Cell 1

Interventions

pembrolizumab 9Nivolumab 4Fluorouracil 4Mohs Surgery 3talimogene laherparepvec 2atezolizumab 2Therapeutics 2Photochemotherapy 2Petrolatum 2Paclitaxel 2Niacinamide 2Aminolevulinic Acid 2tozuleristide 1smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1selinexor 1regorafenib 1peginterferon alfa-2b 1peginterferon alfa-2a 1osimertinib 1nanocis 1methyl 5-aminolevulinate 1fludarabine 1daromun 1cobimetinib 1cemiplimab 1avelumab 1aldesleukin 1aflibercept 1afamelanotide 1Vitamin D 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Imiquimod × Dermatologic × Clear all
NCT00175643 2006-05-09

Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses

University of British Columbia

Phase 3 Completed
20 enrolled
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡